MedTrace Logo

Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

NCT04331119 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2026-05-06

No results posted yet for this study

Summary

The investigators hypothesize that duvelisib maintenance after autologous stem cell transplant in patients with T-cell lymphomas will be safe and well tolerated, and will improve progression free survival.

Conditions

Interventions

DRUG

Duvelisib

SecuraBio will supply duvelisib

PROCEDURE

Peripheral blood draw

-Prior to transplant, cycle 1 day 1 of duvelisib, and at the time of all imaging studies

Sponsors & Collaborators

  • SecuraBio

    collaborator INDUSTRY

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Amanda Cashen, M.D. · Washington University School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2026-04-22
Completion
2026-04-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04331119 on ClinicalTrials.gov